2016) Protective actions of des-acylated ghrelin on brain injury and blood-brain barrier disruption after stroke in mice.
Introduction
Pharmacological treatment of ischemic stroke mainly relies on the use of recombinant tissue plasminogen activator (rt-PA). However, it is only administered to a small proportion of stroke patients due to its propensity to increase the risk of hemorrhage and edema if delayed >4.5 hours after stroke onset. Also, even if rt-PA-induced or spontaneous restoration of blood flow occurs, reperfusion often exacerbates brain injury. Thus, there is a pressing need for novel agents that protect against not only ischemia but also reperfusion injury. A burst of reactive oxygen and nitrogen species generation (ROS & RNS; commonly referred to as oxidative/nitrosative stress) is an important mechanism of neuronal cell death after ischemia and reperfusion (1, 2) . Moreover, such mechanisms also contribute to blood-brain barrier (BBB) disruption after ischemia and reperfusion, as well as dysfunction of arteries upstream of the BBB (3, 4) . There is a growing appreciation of the contribution of these vascular changes to brain injury and edema, and thus the importance of protecting the cerebral endothelium as part of an effective stroke therapy (5) .
Ghrelin is a 28 amino acid peptide hormone produced primarily by the stomach. In the plasma, ghrelin circulates in at least two distinct forms, acylated ghrelin and des-acylated ghrelin. Post-translational addition of a medium-chain fatty acid by the enzyme ghrelin Oacyltransferase (GOAT) produces the acylated form of ghrelin (6) . Acylated ghrelin is a metabolic hormone that stimulates appetite and regulates energy expenditure largely through its actions on the growth hormone secretagogue receptor 1a (GHSR1a) expressed in the hypothalamus and pituitary gland (7) . Des-acylated ghrelin is the most abundant circulating ghrelin form, but it does not bind or activate GHSR1a at physiological concentrations (8) .
Recent evidence suggests that it may have opposing metabolic actions to acylated ghrelin (9) . However, to date, a receptor for des-acylated ghrelin has not been identified. Interest in these peptides has intensified over the past decade with the realization that they may have diverse actions beyond their roles in metabolism (7) . Acylated ghrelin signaling in the brain promotes learning and memory, protects against neurodegeneration (e.g. in Parkinson's disease) by activating UCP2-dependent mitochondrial mechanisms, and has antidepressant and anxiolytic effects (7, 10) . Furthermore, acylated ghrelin (11) (12) (13) and des-acylated ghrelin (11) reduce brain injury in rat models of cerebral ischemia and reperfusion when administered before induction of ischemia, and reduce apoptotic cell death of neurons in vitro (14, 15) . Most importantly, however, it remains to be tested whether these peptides are also protective when ! 5! given after stroke induction, which represents a more clinical relevant scenario. Notably, desacylated ghrelin may also have beneficial effects on the cerebral endothelium after ischemia and reperfusion. Indeed, this ghrelin form suppresses superoxide levels in mouse cerebral vessels by inhibiting the Nox-NADPH oxidases (16) , which are major contributors to oxidative-induced BBB disruption after stroke (17, 18) .
The aims of this study were, therefore, to firstly test the effect of acylated ghrelin and desacylated ghrelin on outcome following transient middle cerebral artery occlusion in mice, when administered after induction of cerebral reperfusion. Secondly, we examined whether the peptides can inhibit BBB disruption by measuring their effects on BBB permeability in vivo, and also cerebral endothelial permeability after oxygen glucose deprivation (OGD) and reoxygenation (RO) in vitro. ! 
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Materials and Methods
This study followed the ARRIVE Guidelines. All experimental procedures were conducted in accordance with the NHMRC guidelines for the care and use of animals for research and were approved by the RMIT University Animal Ethics Committee. A total of 178 male [22 excluded, see below], [8] [9] [10] [11] [12] week old C57Bl6/J mice were obtained from the Animal Resources Centre (Australia). Mice had access to water and standard chow ab libitum, and were housed under a 12:12 light:dark cycle in a SPF facility. Mice were randomly assigned to treatment groups by an investigator not performing surgical procedures or post-surgery analyses, and an investigator blinded to the treatment groups performed post-surgery analyses. In total, 22 stroke mice were excluded from the study which occurred when: (1) there was an inadequate (<70%) reduction in regional cerebral blood flow (rCBF) during the ischemic period or inadequate (>80%) increase within the first 10 min of reperfusion (n=5);
(2) technical complications arose during surgery (e.g. loss of >0.2 mls of blood, n=2; the occluding clamp on the common carotid artery was in place for ≥5 min, n=1); or (3) they died or had to be euthanized (according to clinical severity score) prior to the end of the reperfusion period (n=6 vehicle-treated mice; n=5 acylated ghrelin-treated; and n=3 desacylated ghrelin-treated).
Focal cerebral ischemia and reperfusion
Mice were anesthetized between 7 am and 11 am with a mixture of ketamine (150 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Body temperature was maintained at 37ºC with a heat lamp throughout the procedure and until mice regained consciousness. Focal cerebral ischemia and reperfusion was performed by transient intraluminal filament-induced middle cerebral artery occlusion (tMCAo) as previously described (19) (20) (21) . Regional cerebral blood flow (rCBF) in the area of the cortex supplied by the MCA (~2 mm posterior and 5 mm lateral to bregma) was monitored and recorded prior to the induction of cerebral ischemia, during ischemia, and during the first 10 min of reperfusion using trans-cranial laser-Doppler flowmetry. For sham surgery, the right external carotid artery and common carotid artery were visualized, but the filament was not inserted. After mice had recovered from anaesthesia, they were housed in individual cages. Mice were monitored hourly for a minimum of 8 hours (during 8 am -6 pm) post-surgery and the following morning (7 am) using our monitoring protocol and clinical signs severity scoring system (approved by our ! 7! ethics committee). At the end of the experiment, mice were euthanized with an overdose of isoflurane followed by decapitation.
Ghrelin treatment regime
Mice received three injections of vehicle (0.9% saline, i.p.), acylated ghrelin (1 or 5 mg/kg, i.p.), or des-acylated ghrelin (1 mg/kg, i.p.). Doses were administered at the time of reperfusion, and at 8 and 16 h of reperfusion. Doses were calculated from published work showing neuroprotective effects of these peptides in vivo when administered prior to stroke (11) (12) (13) , and our work showing protective actions of des-acylated ghrelin on cerebral arteries (16) . Acylated ghrelin is known to stimulate food intake, which could in turn improve the well-being and thus influence the recovery of mice. Thus, in a small cohort of mice we measured food intake overnight for 3 days (baseline) prior to sham or stroke surgery and on the night following surgery.
Neurological deficit scoring and functional impairment test
Neurological assessment was performed 24 h after sham or stroke surgery using a five-point scoring system: 0 = normal motor function; 1= flexion of torso and contralateral forelimb when lifted by the tail; 2 = circling to the contralateral side when held by the tail on a flat surface with normal posture at rest; 3 = leaning on the contralateral side at rest; 4 = no spontaneous movement at rest or uncontrolled circling (20) . After neurological assessment and a rest period (10 min), a hanging wire test was performed, as previously described (4, 20) .
Quantification of cerebral infarct and edema volumes
Cerebral infarct and edema volumes were evaluated at 24 h after stroke surgery, as previously described (4, 20) . Briefly, brains were coronally sectioned (30 µm thickness; 420 µm apart) and then stained with 0.1% thionin to delineate the infarct. Total infarct volume was quantified using ImageJ image analysis software, correcting for brain edema, as previously described (4, 20) .
Measurement of cell death using TUNEL
The TUNEL method was used to quantify cell death in brain sections (10 µm) of mice 24 h after stroke, as per manufacturer instructions (In Situ Cell Detection Kit, Roche). Infarcts were located on each section by comparing to corresponding thionin-stained sections. The ! 8! number of TUNEL-positive cells was then counted in both infarct and peri-infarct regions of the ischemic hemisphere. The peri-infarct was assessed as any region outside the infarct in the ischemic hemisphere that displayed TUNEL positive immunoreactive staining (20) . Three sections were analysed per mouse and the total number of TUNEL-positive cells averaged.
Expression levels of cleaved caspase-3
Western blotting was used to measure expression levels of the apoptotic protein cleaved caspase-3 in ischemic/right cerebral hemispheres of mice 24 h after sham or stroke surgery using methods similar to those previously reported (4, 20) . Rabbit polyclonal anti-cleaved caspase-3 (1:1000) and anti-β-actin (1:5000) primary antibodies were used (both from Cell Signaling Technology). Immunoreactive band intensities were normalized to intensity of corresponding bands for β-actin and expressed as fold-change relative to sham.
RT-PCR
RT-PCR was used to measure GHSR1a mRNA expression levels in: (1) ischemic/right cerebral hemispheres of control mice (received no surgical intervention), and of mice 24 h after sham or stroke surgery (vehicle and acylated ghrelin-treated mice). It is known that desacyl ghrelin does not bind to nor activate GHSR1a (8, 22) . Thus, any protective actions of des-acyl ghrelin after stroke will not mediated through GHSR1a. As such, we did not assess GHSR1a mRNA expression levels in brains from des-acylated ghrelin-treated mice; (2) middle cerebral arteries (MCA) of sham and stroke mice; and pituitary of control mice (positive control); and (3) bEnd.3 cells cultured under normoxic or OGD + RO conditions (see below), as previously described (16) . QuantiFast SYBR® Green primers were used (GHSR1a, Cat no. QT00138439; 18s, Cat no. QT02448075). Data were normalized to ribosomal 18s and represented relative to expression levels in either sham (brain) or pituitary gland (cerebral arteries and cells) using the 2 -ΔΔCt method.
Assessment of blood-brain barrier disruption in vivo
4 mL/kg of 2% Evan's blue was injected into the tail vein of mice 21 h after sham or stroke surgery. After 3 h, mice were euthanized by inhalation of isofluorane and transcardially perfused with 0.9% saline. The ischemic/right and contralateral/left hemispheres were then homogenized in N,N-dimethylformamide, incubated overnight at 55°C, and centrifuged.
Supernatants were collected and absorbance read in triplicate, alongside a standard curve of 0-15,000 ng/mL Evan's blue, using a BMG Clariostar plate reader (620 nm excitation, 680 ! 9! nm emission). The amount of Evan's blue per ischemic/right hemispheres (micrograms) was expressed as a ratio of levels in contralateral/left hemispheres.
Oxygen glucose deprivation and reoxygenation of bEnd.3 cells
Mouse microvascular cerebral endothelial cells (bEnd.3 cells; ATCC CRL-2299) were grown in culture media (Dulbecco's modified Eagle's medium [DMEM] containing 10% fetal bovine serum [FBS]) at 37°C in a humidified 5% CO 2 atmosphere. Cells were passaged every 3-4 days. Culture media was changed after 24 h of passaging and every 2 days thereafter.
Experiments were performed with cells from passages 24 to 34.
bEnd.3 cells were washed twice with OGD media composed of glucose-and serum-free DMEM media (Invitrogen) pre-equilibrated for 5 min with 100% N 2 . Cells were then transferred to a humidified hypoxia chamber linked to a digital oxygen controller (0.3% oxygen, Biospherix) filled with 95% N 2 , 5% CO 2 and left to incubate for 1 h at 37°C. Cells were then washed twice with glucose-containing DMEM media (oxygenated with air), and incubated for a further 23 h in glucose-containing DMEM media (no serum) in a humidified normoxic incubator (5% CO 2 atmosphere) at 37°C. For normoxic controls, bEnd.3 cultures were incubated for the same duration of time as the OGD + RO cells in glucose-containing, serum-free medium (equilibrated with air) at 37°C (5% CO 2 atmosphere).
Measurement of paracellular permeability in bEnd.3 cells after OGD + RO
To measure endothelial cell paracellular permeability, the passage of FITC-dextran (70 kDa) across bEnd.3 cells monolayers was measured after exposure to normoxic conditions and OGD + RO. Cells were treated with either vehicle (0.9% saline) acylated ghrelin, or des- incubate for 60 min at 37°C. Inserts were then removed from the wells and samples taken from the lower chamber and transferred into a 96-well black plate. Fluorescence intensity was then measured using the BMG Clariostar plate reader at an excitation (492 nm) and emission (518 nm) wavelength. Fluorescence intensity was calculated as fold-change relative to normoxic controls.
Measurement of tight junction protein expression in bEnd.3 cells after OGD + RO
Western blotting was used to measure expression levels of tight junction proteins occludin, claudin-5, and ZO-1, in bEnd.3 cells exposed to normoxic conditions or OGD + RO, using methods similar to those previously reported (23). Cells were treated with either vehicle (0.9% saline) or des-acylated ghrelin (10 nmol/L) at the time of RO. Mouse monoclonal antioccludin and anti-claudin-5, rabbit polyclonal anti-ZO-1 (Invitrogen; 1:1000 for all antibodies), and anti-β-actin (1:5000, Cell Signaling) primary antibodies were used.
Immunoreactive band intensities were normalized to intensity of corresponding bands for βactin and expressed as fold-change relative to normoxic controls.
Immunofluorescence for ZO-1 and 3-nitrotyrosine in bEnd.3 cells after OGD + RO
bEnd.3 cells were seeded onto glass coverslips in culture media (DMEM media with 10% FBS). 2 days post-confluence, cells were exposed to normoxic conditions or OGD + RO Western blot analysis indicated that expression of cleaved caspase-3 (17 kDa subunit) was significantly increased in ischemic hemispheres of vehicle-treated mice relative to sham mice (P<0.05, Figure 2B ). Consistent with our infarct and TUNEL data, expression levels of cleaved caspase-3 in ischemic hemispheres of acylated ghrelin-treated mice were comparable to that of vehicle-treated mice (P<0.05, Figure 2B ). By contrast, expression levels in ischemic hemispheres of des-acylated ghrelin-treated mice (1 mg/kg) were significantly lower than in vehicle-treated mice (P<0.05, Figure 2C ) and comparable to levels in sham mice (P>0.05). Expression levels of the 19 kDa subunit of cleaved caspase-3 were similar between sham (0.35 ± 0.04, relative intensity to β-actin), vehicle-treated (0.44 ± 0.04), and des-acylated ghrelin-treated mice (0.36 ± 0.05; P>0.05).
Effect of stroke on GHSR1a mRNA expression
Using RT-PCR, we next tested whether acylated ghrelin's lack of effect on stroke outcome relates to down-regulation of its receptor, GHSR1a, in the ischemic hemisphere. Expression levels of GHSR1a mRNA in the brain were similar between control and sham-operated mice, indicating that anaesthesia/surgery per se does not affect GHSR1a expression ( Figure 3A) . In vehicle-treated stroke mice, GHSR1a mRNA expression was significantly lower relative to control and sham mice (P<0.05), whereas levels were not decreased in mice treated with acylated ghrelin (1 mg/kg). Thus, post-stroke treatment with acylated ghrelin prevents downregulation of its receptor in the ischemic brain.
We have previously reported that although GHSR1a mRNA is expressed at low levels in mouse cerebral arteries, it is not expressed at the protein level (16) . Similarly, we found here that GHSR1a mRNA expression in cerebral arteries of sham-operated mice was very low (~22-fold lower relative to pituitary [positive control]; P<0.05, Figure 3B ), and expression levels were negligible in cerebral arteries of stroke mice (~14-fold lower relative to shamoperated, P<0.05). Similarly, GHSR1a mRNA expression was negligible in bEnd.3 cells cultured under either normoxic or OGD conditions (~2200-fold lower relative to pituitary, P<0.05, data not shown). Thus, acylated ghrelin is unlikely to mediate direct effects on the mouse cerebral endothelium due to the lack of GHSR1a.
Des-acylated ghrelin reduces BBB disruption
There was marked extravasation of Evan's blue into ischemic hemispheres of vehicle-treated mice, indicative of increased BBB permeability and thus BBB disruption ( Figure 4A Acylated ghrelin (10 nmol/L) had no effect on paracellular hyper-permeability of bEnd.3 exposed to OGD + RO ( Figure 4B 
Effect of des-acylated ghrelin on tight junction protein expression in bEnd.3 cells
Western blot analysis showed that expression of occludin and ZO-1 were reduced in vehicletreated cells after OGD + RO relative to normoxic (P<0.05, Figure 5A and B). The decline in occludin levels was virtually prevented by des-acylated ghrelin (10 nmol/L; post-treatment, P<0.05, Figure 5A ); however, it had no significant effect on ZO-1 expression ( Figure 5B ). Expression of claudin-5 was unchanged in vehicle-treated cells after OGD + RO (P>0.05, Figure 5C ). Treatment with des-acylated ghrelin significantly increased expression levels (P<0.05, Figure 5C ).
In accordance with our Western blot data, immunofluorescence staining for ZO-1 appeared to be less intense in vehicle-treated cells. Also, ZO-1 immunoreactivity was more discontinuous along the cell membrane than normoxic controls, which might suggest re-distribution of this protein ( Figure 5D ). In cells treated with des-acylated ghrelin, ZO-1 immunoreactivity was also less in intense; however, there appeared to be a more continuous alignment of ZO-1 to the cell membrane.
Effect of des-acylated ghrelin on viability and caspase-3 expression in bEnd.3 cells
After exposure to OGD + RO, the viability of vehicle-treated bEnd.3 cells was decreased by >20% relative to normoxic controls ( Figure 5E, P<0.05) . Treatment of cells with des-acylated ghrelin significantly increased cell viability relative to vehicle-treated cells (P<0.05).
Western blot analysis revealed a significant increase in expression levels of cleaved caspase-3 (17 kDa subunit) in vehicle-treated and des-acylated ghrelin-treated cells exposed to OGD + ! 16! RO (P<0.05, Figure 5F ), and levels were comparable between vehicle-and des-acylated ghrelin treated cells. The 19 kDa subunit was undetectable in either normoxic or OGD + RO cells.
Des-acylated ghrelin attenuates superoxide levels, Nox activity, and 3-nitrotyrosine in bEnd.3 cells
After exposure to OGD + RO, basal superoxide production by bEnd.3 cells was ~2.5-fold greater than levels generated by normoxic cells, as measured by L-012-enhanced chemiluminescence (P<0.05, Figure 6A ). However, in des-acylated ghrelin-treated cells, superoxide production was decreased by ~40% (P<0.05). We also found that ethidium/oxyethidium fluorescence appeared to be less intense in cells treated with desacylated ghrelin relative to vehicle-treated ( Figure 6B ). PEG-SOD also appeared to significantly reduce fluorescence intensity, confirming that superoxide was the major ROS detected by DHE.
Angiotensin II is known to increase superoxide production by cerebral vessels by activating the Nox-NADPH oxidases (Nox1-and Nox2-containing isoforms) and is commonly used to assess Nox activity in vessel preparations and vascular cells (16, 27, 28) . Acylated ghrelin (0.1-10 nmol/l) had no significant effect on Nox activity, which is also consistent with our findings in intact mouse cerebral vessels (16) ( Figure 6C ). Similar to its inhibitory effect on Nox activity in intact mouse cerebral arteries (16) , des-acylated ghrelin (1-10 nmol/L) markedly reduced angiotensin II-stimulated superoxide generation (~50 %), and thus Nox activity, in bEnd.3 cells exposed to normoxic conditions ( Figure 6D , P<0.05). After exposure to OGD + RO, angiotensin II-stimulated superoxide generation was increased ~2-fold in vehicle-treated bEnd.3 cells relative to normoxic controls (P<0.05, Figure 6E ). Moreover, treatment with des-acylated ghrelin prevented this increase in Nox activity such that superoxide levels were comparable to levels in normoxic controls (P>0.05).
Using immunofluorescence and semi-quantitative analysis, we found that 3-nitrotyrosine expression (marker of protein nitration by peroxynitrite) was increased by ~2-fold in bEnd.3 cells after OGD + RO (P<0.05, Figure 7) . Importantly, treatment with des-acylated ghrelin significantly reduced expression levels (P<0.05, Figure 7 ). ! 17!
Discussion
Our data demonstrate that the des-acylated form of ghrelin improves functional and neurological deficit, and reduces the degree of injury, apoptosis, and swelling when administered to mice shortly after induction of reperfusion. By contrast, at the two doses we tested, acylated ghrelin fails to improve these end-point measures of stroke outcome. This study also reveals that the beneficial effect of des-acylated ghrelin relates, at least in part, to its ability to protect against BBB disruption. Moreover, this effect occurs in association with reduced ROS/RNS production and Nox activity, inferring des-acylated ghrelin enhances BBB integrity by reducing oxidative/nitrosative damage.
When administered prior to or at the immediate onset of ischemia, acylated ghrelin reduces brain injury in rat models of ischemia and reperfusion through anti-apoptotic and antiinflammatory mechanisms (11) (12) (13) . By contrast, we have shown here that treatment with 1 mg/kg acylated ghrelin after induction of reperfusion failed to improve several end-point measures of stroke outcome, with no significant reduction in infarct, swelling, or apoptosis (TUNEL or cleaved caspase-3 expression), and no improvement in neurological or motor performance. Similarly, even a 5-fold higher dose of acylated ghrelin had no beneficial effect on these measures of post-stroke outcome. Interestingly, the neuroprotective effects of acylated ghrelin in a mouse model of Parkinson's disease are dependent on metabolic status. Specifically, acylated ghrelin was neuroprotective when administered to fasted mice, whereas it had no effect during ab libitum feeding (29) . Here, we studied mice that had been fed ab libitum prior to stroke surgery. However, food intake was markedly reduced after stroke induction (~90%), which is consistent with the tMCAo model of stroke (30) . Thus, although the mice were fed ab libitum prior to stroke surgeries, there were in fact in a relatively 'fasted state' during the treatment regime. Notably, of the studies showing the protective actions of acylated ghrelin when administered pre-stroke, only one study detailed that rats were fasted overnight prior to surgery and acylated ghrelin administration (31) , whereas the remaining studies did not describe whether there were fasted or fed ab libitum (11) (12) (13) .
Although GHSR1a mRNA expression levels were decreased in ischemic hemispheres of vehicle-treated mice, levels in mice treated with acylated ghrelin were comparable to shamoperated mice, showing that post-stroke treatment up-regulates GHSR1a. Consistent with this, other studies have shown that peripheral administration of acylated ghrelin up-regulates GHSR1a expression (12, 32) . However, the mechanisms underpinning this effect are ! 18! unknown. Nevertheless, our data indicate that down-regulation of acylated ghrelin's receptor does not account for its lack of effect on stroke outcome. Importantly, acylated ghrelin's appetite stimulating properties may be altered after stroke, actions that are largely mediated through the hypothalamus. Specifically, we found that acylated ghrelin had no effect on food intake by stroke mice during the treatment period, whereas it increased intake in sham controls. This finding raises the possibility of a generalized 'resistance' to acylated ghrelin in the acute period after stroke, which may extend to extra-hypothalamic brain regions involved in infarct development. An additional and plausible explanation for the apparent timedependence of acylated ghrelin's protective effects could relate to its ability to more effectively prevent/inhibit mechanisms of ischemia-related injury than those caused by reperfusion (see discussion below). Irrespective of the reasons, our findings suggest that the timing of administration may be critical for acylated ghrelin's neuroprotective effects, casting doubts on it suitability for development as an acute stroke therapy.
Des-acylated ghrelin is structurally identical to the acylated form apart from the absence of a medium-chain fatty acid at serine position 3, which is essential for activity at GHSR1a (7) .
Despite this, des-acylated ghrelin often produces distinct biological effects to that of the acylated form. For example, we have recently shown that it exerts protective effects on cerebral arteries (e.g. suppressing Nox oxidase activity), whereas acylated ghrelin has no effect (16) . In contrast to acylated ghrelin, post-stroke administration of des-acylated ghrelin was protective, with a marked reduction in both infarct and swelling at 24 hours, and an improvement in neurological and motor performance. In rodents, the vast majority (~70-80%) of the infarct volume development takes place during the first 24 hours (33). However, we cannot exclude the possibility that des-acylated ghrelin slowed the evolution of ischemic damage rather than reducing final infarct volume. Next we found evidence that this beneficial effect of des-acylated ghrelin was related to the degree of apoptosis in the ischemic hemisphere. Specifically, des-acylated ghrelin reduced the number of TUNEL-positive cells in peri-infarct regions, and prevented the increase in cleaved caspase-3 expression. Desacylated ghrelin is known to directly protect neurons against ischemia-like conditions in vitro through anti-apoptotic mechanisms (15) , thus it is likely that direct neuroprotective actions contribute des-acylated ghrelin's beneficial effect on infarct volume in vivo.
There is a growing appreciation of the importance of protecting the cerebral endothelium as part of an effective stroke therapy. Thus, we next tested the effects of the peptides on BBB ! 19! disruption in vivo and in vitro. Consistent with its lack of effect of stroke outcomes, acylated ghrelin had no beneficial effect on BBB permeability in vivo or the hyper-permeability of cerebral microvascular endothelial cells exposed to OGD + RO in vitro. This may relate, at least in part, to the lack of GHSR1a in the cerebral vasculature (16) and cerebral microvascular endothelial cells. Thus, it is highly improbable that acylated ghrelin modulates end-point measures of BBB disruption such as tight junction protein expression, cell viability, and apoptosis. Hence, we did not examine the effect of acylated ghrelin on these end-point measures in bEnd.3 cells exposed to OGD + RO. Des-acylated ghrelin on the other hand strongly protected against BBB hyper-permeability and thus BBB disruption in vivo.
Moreover, it attenuated the hyper-permeability of cerebral microvascular endothelial cells when administered either before OGD or at the time of RO, inferring that direct effects on the cerebral endothelium contribute to its beneficial actions on BBB integrity in vivo. In accordance with the permeability data, des-acylated ghrelin prevented the loss of the tight junction protein occludin, increased levels of claudin-5, and appeared to reduce of ZO-1 redistribution from the cell membrane to the cytosol. Des-acylated ghrelin also inhibited the death of cerebral endothelial cells exposed to OGD + RO, however, this occurred independently of a reduction in cleaved caspase-3 expression. The lack of effect of desacylated ghrelin on cleaved caspase-3 expression is clearly in contrast to our earlier data showing that it markedly reduces expression levels in the ischaemic hemispheres of mice after stroke. It is conceivable that apoptotic pathways triggered in whole brain after ischaemia and reperfusion differ from those of cerebral microvascular endothelial cells. Thus, we presume that des-acylated ghrelin reduces death of bEnd.3 cells through caspase-3independent anti-apoptotic pathways and/or necrotic cell death. Taken together, these data suggest that des-acylated ghrelin protects against BBB disruption by preventing the loss of tight junction integrity and by inhibiting endothelial cell death.
During early reperfusion, excess ROS/RNS formation by cerebral endothelial cells (and other
cell types) triggers a number of downstream pathways that can directly mediate BBB disruption. Moreover, the Nox-NADPH oxidases are a significant source of ROS during reperfusion injury (4, 17, 18, 21, 34) . Several lines of evidence indicate that des-acylated ghrelin may protect against BBB disruption by targeting these mechanisms. Firstly, desacylated ghrelin has powerful ROS limiting properties in peripheral endothelial cells (35) and cerebral vessels (16) . Indeed, we have shown that des-acylated ghrelin suppresses superoxide generation by cerebral arteries from 'non-stroked' mice via inhibition of the Nox oxidases. data from this study indicate that unlike the des-acylated form, acylated ghrelin does not modulate ROS levels in cerebral vessels or inhibit cerebral vascular Nox oxidases. As such, this could be one possible reason why this ghrelin form is ineffective when administered during reperfusion, whereas des-acylated ghrelin strongly protects. Notably, Nox oxidases are also a major source of pathological ROS in endothelial cells of arteries upstream of the BBB, resident brain cells (e.g. neurons and microglia) and infiltrating leukocytes after stroke (4, 36) . Des-acylated ghrelin could therefore improve stroke outcome by inhibiting the Nox oxidases in these cell types.
In summary, this study has revealed protective actions of des-acylated ghrelin when administered after initiating post-ischemic reperfusion, which involve a previously unrecognized beneficial effect on BBB integrity. Notably, we have shown previously that des-acylated ghrelin is a potent stimulator of vasodilator NO in cerebral vessels (16) , and thus might also improve stroke outcome by supporting perfusion of the ischemic brain. Thus, taken together with its known direct neuroprotective actions (15) , this study sheds light on the potential of des-acylated ghrelin (or longer-acting analogues, e.g. AZP-531 -currently in clinical trials for the treatment of obesity/type II diabetes) as a novel therapeutic agent that can target both neuronal and vascular mechanisms of ischemia/reperfusion-induced injury.
Lastly, our findings may prove to be all the more crucial when we consider that its production may be reduced after stroke and in patients with stroke risk factors (37) . 
